23 Dec
2015
16:30 E.S.T.

Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies

Read more

21 Dec
2015
16:30 E.S.T.

Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016

Read more

19 Nov
2015
16:30 E.S.T.

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Read more

16 Nov
2015
16:30 E.S.T.

Cellectis Reports Third Quarter and First Nine Months 2015 Financial Results

Read more

05 Nov
2015
16:30 E.S.T.

UCART19: First in Man Proof of Concept to be Presented at 2015 ASH Annual Meeting

Read more

28 Oct
2015
16:30 E.S.T.

Successful GMP Production Process for UCART19

Read more

09 Sep
2015
16:30 E.S.T.

Cellectis Reports Second Quarter and First Half Year 2015 Financial Results

Read more

03 Sep
2015
16:30 E.S.T.

MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy

Read more

27 Aug
2015
16:30 E.S.T.

Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences

Read more

16 Jul
2015
16:30 E.S.T.

Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies

Read more